Bevacizumab Archives - Medical Conferences

Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time

Presented By

Dr Adam Yopp, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, IMbrave050

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:13

More highlights in Colorectal Cancer

Trial

POCHI, LEANOX

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:48

Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC

Presented By

Dr Sangdao Boonkaya, King Chulalongkorn Memorial Hospital, Thailand

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:46

EMERALD-1: TACE plus immunotherapy meets primary endpoint in unresectable HCC

Presented By

Dr Riccardo Lencioni, University of Pisa, Italy

Trial

Phase 3, EMERALD-1

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:57

Clinical biomarkers may guide therapy selection in RAS wildtype mCRC

Presented By

Dr Julian Holch, Ludwig-Maximilians-University of Munich, Germany

Trial

Phase 3, FIRE-3 (AIO KRK0306)

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:31

Investigational agent DKN-01 promising for advanced MSS CRC

Presented By

Dr Meredith Pelster, Sarah Cannon Research Institute, TN, USA

Trial

Phase 2, DeFianCe

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:10

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By

Dr Philipp Harter, Kliniken Essen-Mitte, Germany

Trial

Phase 3, DUO-O

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:44

IMbrave 151 missed primary endpoint in advanced BTC

Presented By

Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 2, IMbrave151

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:15

Mutation-based selection to identify patients suitable for panitumumab treatment

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:01

SUNLIGHT trial meets primary endpoint in refractory metastatic CRC

Presented By

Prof. Josep Tabernero, Val d’Hebron University Hospital and Institute of Oncology, Spain

Trial

Phase 3, SUNLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:45

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:19

Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases

Presented By

Prof. Cornelis Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:11

ASCO 2022 Highlights Podcast

Presented By

Dr Robert van den Heuvel, Medicom

Conference

ASCO 2022

21 June 2022 09:38

Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC

Presented By

Dr Hyeyeong Kim, Ulsan University Hospital, South Korea

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:00

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy

Trial

Phase 2, MAYA & AtezoTRIBE

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:42

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By

Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy

Trial

Phase 3, KEYNOTE-826

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:23

Real-world data shows inferior survival compared with IMpower150 results

Presented By

Dr Samantha Dean, Austin Health, Australia

Trial

Phase 3, IMpower150

Conference

WCLC 2021

Type

News article

21 September 2021 13:23

Novel drug combination for recurrent ovarian cancer

Presented By

Prof. David O’Malley, Ohio State University, OH, USA

Trial

Phase 1/2, FORWARD II

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:43

Landmark OS for HCC, updated IMbrave150 data

Presented By

Prof. Richard Finn, UCLA, USA

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:39

Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers

Presented By

Prof. Thomas Seufferlein, University of Ulm, Germany

Trial

Phase 1/2, PERMAD

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:37

Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy

Presented By

Prof. Eric Van Cutsem, KU Leuven, Belgium

Trial

Phase 2, TASCO1

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:35

Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:58

Treatment of newly diagnosed ovarian cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:39

Understanding MIBC biology for novel treatment options

Presented By

Prof. Yohann Loriot, Université Paris-Saclay, France

Trial

BLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 12:36

Ovarian cancer patients benefit from combined maintenance therapy

Presented By

Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:25

Adding bevacizumab to temozolomide-based therapy in neuroblastoma

Trial

Phase 2, BEACON-Neuroblastoma

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:29

FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis

Presented By

Dr Javier Sastre, Hospital Clínico San Carlos, Spain

Trial

Phase 3, VISNU-1

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 23:53

Other I-O combinations

Presented By

Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland

Trial

IMpower 150

Conference

ELCC 2019

25 June 2019 21:17

Combination therapies: Where are we in 2018?

Presented By

Prof. Martin Reck, German Center for Lung Research, Germany

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:05